230 related articles for article (PubMed ID: 26757732)
1. CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.
Westbrook JA; Cairns DA; Peng J; Speirs V; Hanby AM; Holen I; Wood SL; Ottewell PD; Marshall H; Banks RE; Selby PJ; Coleman RE; Brown JE
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26757732
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer.
Westbrook JA; Wood SL; Cairns DA; McMahon K; Gahlaut R; Thygesen H; Shires M; Roberts S; Marshall H; Oliva MR; Dunning MJ; Hanby AM; Selby PJ; Speirs V; Mavria G; Coleman RE; Brown JE
J Pathol; 2019 Mar; 247(3):381-391. PubMed ID: 30426503
[TBL] [Abstract][Full Text] [Related]
3. Expression of Yes-associated protein (YAP) in metastatic breast cancer.
Kim HM; Jung WH; Koo JS
Int J Clin Exp Pathol; 2015; 8(9):11248-57. PubMed ID: 26617849
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
Cancer; 2012 Apr; 118(8):2039-47. PubMed ID: 22139648
[TBL] [Abstract][Full Text] [Related]
6. Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
Brown J; Rathbone E; Hinsley S; Gregory W; Gossiel F; Marshall H; Burkinshaw R; Shulver H; Thandar H; Bertelli G; Maccon K; Bowman A; Hanby A; Bell R; Cameron D; Coleman R
J Natl Cancer Inst; 2018 Aug; 110(8):871-879. PubMed ID: 29425304
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
[TBL] [Abstract][Full Text] [Related]
8. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Lipton A; Fizazi K; Stopeck AT; Henry DH; Brown JE; Yardley DA; Richardson GE; Siena S; Maroto P; Clemens M; Bilynskyy B; Charu V; Beuzeboc P; Rader M; Viniegra M; Saad F; Ke C; Braun A; Jun S
Eur J Cancer; 2012 Nov; 48(16):3082-92. PubMed ID: 22975218
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
Zhao X; Xu X; Zhang Q; Jia Z; Sun S; Zhang J; Wang B; Wang Z; Hu X
BMC Cancer; 2011 Sep; 11():403. PubMed ID: 21936956
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
11. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
[TBL] [Abstract][Full Text] [Related]
12. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
[TBL] [Abstract][Full Text] [Related]
13. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).
von Minckwitz G; Rezai M; Tesch H; Huober J; Gerber B; Zahm DM; Hilfrich J; Costa SD; Dubsky P; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Fasching PA; Schneeweiss A; Paepke S; Untch M; Burchardi N; Mehta K; Loibl S;
Eur J Cancer; 2016 Sep; 64():12-21. PubMed ID: 27323347
[TBL] [Abstract][Full Text] [Related]
14. Breast-cancer adjuvant therapy with zoledronic acid.
Coleman RE; Marshall H; Cameron D; Dodwell D; Burkinshaw R; Keane M; Gil M; Houston SJ; Grieve RJ; Barrett-Lee PJ; Ritchie D; Pugh J; Gaunt C; Rea U; Peterson J; Davies C; Hiley V; Gregory W; Bell R;
N Engl J Med; 2011 Oct; 365(15):1396-405. PubMed ID: 21995387
[TBL] [Abstract][Full Text] [Related]
15. Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study.
Brown J; Paggiosi MA; Rathbone E; Gregory W; Bertelli G; Din O; McCloskey E; Dodwell D; Cameron D; Eastell R; Coleman R
J Bone Miner Res; 2024 Mar; 39(1):8-16. PubMed ID: 38630878
[TBL] [Abstract][Full Text] [Related]
16. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.
Brown JE; Cook RJ; Lipton A; Coleman RE
Clin Cancer Res; 2012 Nov; 18(22):6348-55. PubMed ID: 22952345
[TBL] [Abstract][Full Text] [Related]
17. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.
Yan T; Yin W; Zhou Q; Zhou L; Jiang Y; Du Y; Shao Z; Lu J
Eur J Cancer; 2012 Jan; 48(2):187-95. PubMed ID: 22100904
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
